Key Events This Week
27 Jul: New 52-week high at Rs.248.80
28 Jul: Further 52-week high at Rs.253.75
29 Jul: New 52-week high at Rs.258.80
30 Jul: 52-week high extended to Rs.263.95; valuation shifts noted
31 Jul: Week closes with new 52-week high at Rs.269.20

Bafna Pharmaceuticals Ltd is Rated Sell
2026-08-01 10:10:04Bafna Pharmaceuticals Ltd is currently rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's present position as of 01 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article











